Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA

About this update from Fagron Sa

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Rafael Padilla, CEO of Fagron : “I am incredibly pleased with the performance we delivered in 2025. Growth was broad-based across regions and segments, supported by our diversified model, disciplined commercial execution and continued progress on operational excellence. Product availability across the Group was above 90%, while procurement and manufacturing savings were also ahead of target. In EMEA, we delivered a resilient performance, supported by geographical diversification and the integration of recent acquisitions. Latin America maintained strong momentum, particularly in Brazil, driven by our Brands portfolio and innovation pipeline. North America–Pacific continued to benefit from outsourcing demand and the onboarding of new customers, alongside ongoing efficiency initiatives. We also witnessed significant M&A activity, expanding our footprint and capabilities in a disciplined, value-creating manner. Integration is progressing as planned, and we remain focused on execution and the capture of synergies. Looking ahead, we remain confident in our strategy and are well positioned to capture attractive growth opportunities while continuing to strengthen quality, operational performance and cash generation. We remain on track to achieve our mid-term objectives.” Attachment

View stock analysis, news, and events for Fagron Sa